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New Findings 41 
The central question of this study was to evaluate the degree to which increases in haematocrit 42 
alter cerebral blood flow and cerebral oxygen delivery during acclimatization to high-altitude.  43 
Through haemodilution, we determined that, following one-week of acclimatization, the primary 44 
mechanism contributing to the cerebral blood flow response during acclimatization is increases in 45 
haemoglobin and haematocrit, while the remaining contribution to the cerebral blood flow 46 
response during acclimatization is likely attributable to ventilatory acclimatization. 47 
 48 
ABSTRACT 49 
At high-altitude, increases in haematocrit (Hct) are achieved through altitude-induced diuresis 50 
and erythropoiesis, both of which result in increased arterial oxygen content (CaO2). Given the 51 
impact alterations in Hct have on CaO2, haemoconcentration has been hypothesized to partly 52 
mediate the attenuation of the initial elevation in cerebral blood flow (CBF) at high-altitude. To 53 
test this hypothesis, healthy males (n=13) ascended to 5050 m over nine days without the aid of 54 
prophylactic acclimatization medications. Following one-week of acclimatization at 5050 m, 55 
participants were haemodiluted by rapid saline infusion (2.10±0.28 L) to return Hct towards pre-56 
acclimatized levels. Arterial blood gases, Hct, global CBF (duplex ultrasound), and 57 
haemodynamic variables were measured following initial arrival to 5050 m, and after one-week 58 
of acclimatization at high-altitude, prior to and following the haemodilution protocol. Following 59 
one-week at 5050m, Hct increased from 42.5±2.5 to 49.6±2.5 % (P<0.001), and was 60 
subsequently reduced to 45.6±2.3 % (P<0.001) following haemodilution. Global CBF decreased 61 
from 844±160 to 619±136 mL/min (P=0.033) following one-week of acclimatization and 62 
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increased to 714±204 mL/min (P=0.045) following haemodilution. Despite the significant 63 
changes in Hct, and thus CaO2, cerebral oxygen delivery was unchanged at all time points. 64 
Furthermore, these observations occurred in the absence of any changes in mean arterial blood 65 
pressure, cardiac output, arterial blood pH, or oxygen saturation pre- and post-haemodilution. 66 
These data highlight the influence of Hct in the regulation of CBF and are the first to demonstrate 67 
experimentally that haemoconcentration contributes to the reduction in CBF during 68 
acclimatization to altitude. 69 
 70 
INTRODUCTION  71 
A reduction in the partial pressure of atmospheric oxygen results in hypoxemia, whereby 72 
necessary cerebrovascular responses are required to maintain adequate cerebral oxygen delivery 73 
(CDO2). Upon ascent to high-altitude, cerebral blood flow (CBF) increases in proportion to the 74 
degree of hypoxemia to compensate for the reduced arterial oxygen content (CaO2) (Severinghaus 75 
et al., 1966; Ainslie & Subudhi, 2014). Within two- to three-days following initial arrival to high-76 
altitude, CBF begins to decrease, returning to sea-level values typically between 7-14 days at a 77 
given altitude (Willie et al., 2014), yet no mechanism(s) have been clearly ascribed to this pattern 78 
of CBF changes. It is well established that hypoxic CBF regulation is driven by changes in CaO2 79 
to maintain consistent CDO2 during arterial hypoxemia at sea-level [reviewed in: (Hoiland et al., 80 
2016)]. This regulation of blood flow is similar to that of the systemic circulation during exercise 81 
(Roach et al., 1999; Gonzalez-Alonso et al., 2001), whereby flow is coupled to CaO2, but not the 82 
partial pressure of arterial oxygen (PaO2). Thus, the pattern of CBF changes observed at high-83 
altitude are also likely regulated by changes in CaO2 (Ainslie & Subudhi, 2014; Hoiland et al., 84 
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2018). The primary factors influencing CaO2 at high-altitude, and by association CBF, are 85 
changes in arterial oxygen saturation (SaO2), hematocrit (Hct). This is in addition to the well 86 
documented influence of the partial pressure of carbon dioxide (PaCO2) and pH on CBF. 87 
Alterations in cerebrovascular reactivity to CaO2 and/or PaCO2 may also underlie changes in CBF 88 
at altitude (Lucas et al., 2011; Willie et al., 2015) although their contribution to CBF changes 89 
during acclimatization is likely modest at best [reviewed in: (Hoiland et al., 2018)].  90 
Early increases in Hct occur through high-altitude induced diuresis whereby elevated 91 
arterial pH stimulates bicarbonate to be excreted by the kidneys through the urine, reducing 92 
plasma volume. This response partially mitigates the initial reductions in CaO2 (Pugh, 1964; Ryan 93 
et al., 2014; Siebenmann et al., 2017). Thereafter, following approximately one-week at altitude, 94 
Hct increases further through erythropoiesis (Siebenmann et al., 2017). While PaO2 and SaO2 95 
increase and PaCO2 decreases as a result of ventilatory acclimatization [reviewed in: (Hoiland et 96 
al., 2018], previous research has speculated that increased Hct provides a greater input into the 97 
changes in CaO2 observed at altitude. Indeed, estimations indicate Hct may account for 60-70% 98 
of the increase in CaO2 during acclimatization, and therefore possess a commensurate influence 99 
on the reduction in CBF observed across acclimatization (Hoiland et al., 2018). Importantly, 100 
CaO2 regulates hypoxic vasodilation via changes in PaO2/SaO2 as well as independent of 101 
alterations in PaO2/SaO2 such as when Hct is altered [reviewed in: (Hoiland et al., 2016)]. 102 
However, this regulation of CBF by Hct appears unrelated to changes in blood viscosity [(Brown 103 
& Marshall, 1985; reviewed in: Hoiland et al 2016)]. This understanding of the fundamental 104 
importance of CaO2 in the regulation of hypoxic cerebral vasodilation has been long standing 105 
(Brown et al., 1985); however, the influence of Hct on CBF during acclimatization at altitude due 106 
to its relationship with CaO2 has never been experimentally determined.  107 
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The aim of this study was to evaluate the degree to which Hct alters CBF and CDO2 by 108 
acutely haemodiluting subjects to pre-acclimatized Hct concentrations observed upon initial 109 
arrival to 5050 m. We hypothesized that following approximately seven days of acclimatization at 110 
5050 m above sea-level, CBF would be significantly decreased from initial arrival values 111 
concomitant with an increase in Hct. Further, we hypothesized that following haemodilution, due 112 
to the experimentally isolated reduction in Hct, CBF would concomitantly increase and thus be 113 
partially restored to near pre-acclimatized levels.  114 
  115 
METHODS  116 
  117 
Ethical approval  118 
All participants gave written informed consent prior to participating. This study was 119 
approved by the University of British Columbia Clinical Research Ethics Board, the Nepal Health 120 
Research Council, and conformed to the standards set by the Declaration of Helsinki (except 121 
registry in a database) and the Canadian Government Tri-council Policy Statement (TCPS2) for 122 
integrity in research.  123 
  124 
Participants  125 
Thirteen healthy male participants (BMI: 23.2 ± 2.1 kg · m 
-2
, Age: 27 ± 5 years) were 126 
recruited to participate in this study. Participants were recruited at the University of British 127 
Columbia’s Okanagan campus and were part of the research team. This project was part of a 128 
larger expedition to the EV-K2-CNR Italian Pyramid Research laboratory in the Khumbu Valley, 129 
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Nepal at 5050 m that took place September to November 2016 (Willie et al., 2018). Although 130 
participants were recruited to other projects at the Pyramid Laboratory, all arrived to high-altitude 131 
at the same time and were tested >5 half-lives following any drug interventions. Further, all 132 
participants abstained from exercise, caffeine, and alcohol for 24 hours prior to testing and 133 
arrived having fasted for >4 hours. All participants were born and lived at or near sea-level and 134 
were free of cardiovascular, respiratory and neurological diseases and were non-smokers. One 135 
participant was taking Pentasa®, a medication used to treat inflammatory bowel disease, 136 
throughout the entire study. 137 
  138 
Experimental Overview  139 
The research team travelled to Nepal to begin the ascent to high-altitude. All participants 140 
spent 3-9 days in Kathmandu (1400 m) prior to flying to Lukla (2860 m) to begin the trek to the  141 
EV-K2-CNR Pyramid Research Laboratory (5050 m). Ascent to the Pyramid Laboratory took 142 
place over a slow and safe 9-day trek without the use of any acute mountain sickness 143 
prophylactics  144 
(e.g., acetazolamide). Participants spent one night in Monjo (2800 m), three nights in Namche 145 
Bazaar (3400 m), one night in Deboche (3820 m), and then three nights in Pheriche (4371 m) 146 
followed by the final trekking day to the Pyramid Laboratory (5050 m). Due to the length of 147 
testing per participant, and hours available for testing at the remote laboratory, testing was limited 148 
to two participants per day. As such, participants underwent the haemodilution protocol across a 149 
small range of relative acclimatization with testing conducted on days 4-10 (avg. 7) at the 150 
Pyramid Laboratory (Figure 1). For more details on the ascent see (Willie et al., 2018).   151 
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The day following initial arrival to the pyramid lab (i.e. day 1), subjects lay supine for 20 152 
minutes of quiet rest, after which CBF, echocardiography and arterial blood samples were 153 
acquired. A minimum of 24 hours prior to the main experimental protocol participants’ blood 154 
volumes were measured using the Carbon Monoxide Rebreathe technique (Schmidt & Prommer, 155 
2005). This protocol is detailed in the following section (Experimental Measures). The following 156 
day, participants completed the experimental protocol prior to and following haemodilution. After  157 
20 minutes of quiet supine rest participants were cannulated, following which, CBF, cardiac 158 
output (Q), and radial arterial blood measures were acquired. A hypervolemic haemodilution 159 
protocol was performed in an attempt to return Hct and plasma volume to pre-acclimatized values 160 
observed upon initial arrival at high-altitude (i.e., Hct ≈ 45 %) through rapid saline infusion (0.9 161 
% NaCl). Prior to expedition testing, pilot work was conducted to determine the adequate 162 
infusion volume of saline required to elicit the desired decrease in Hct. A bolus infusion of saline 163 
equal to between 30-35 % of the participants total blood volume (avg 2.10 ± 0.28 L) was infused 164 
over 0.5-1 hr.   165 
  166 
Experimental Measures  167 
A radial artery catheter (20-gauge; Arrow, Markham, ON, Canada) was inserted into the 168 
left radial artery under local anesthesia (Lidocaine, 1.0%) and ultrasound guidance using sterile 169 
technique. The arterial catheter was attached to an inline waste-less sampling system (Edwards 170 
Lifesciences, VAMP, CA, USA) and a pressure transducer that was placed at the height of the 171 
right atrium (TruWave transducer). Following cannulation, subjects rested quietly for 20-minutes, 172 
after which an arterial blood sample was taken, and analyzed (ABL90 FLEX, Radiometer, 173 
Copenhagen, Denmark).   174 
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Internal carotid artery (ICA) and vertebral artery (VA) image acquisition was obtained 175 
using a 10 MHz multi-frequency linear array probe attached to a high-resolution ultrasound 176 
machine (15L4, Terason t3200, Burlington, MA, USA). Arterial diameter was measured with B-177 
mode imaging while pulse-wave mode simultaneously measured blood velocity within the vessel. 178 
Image location was selected on an individual basis in order to ensure clear, highly reproducible 179 
measures with VA imaging occurring between cervical vertebrate 4 and 5, 5 and 6 or proximal to 180 
entry into the vertebral column and ICA imaging taken ≥1.5 cm distal to the common carotid 181 
bifurcation. The sum of both ICA and VA flow multiplied by two was used to estimate global 182 
cerebral blood flow (gCBF). Cerebrovascular reactivity to CaO2 was also assessed using the 183 
concurrent ultrasound blood flow values and arterial blood samples. CaO2 was calculated from 184 
the arterial blood sample utilizing the arterial SpO2, PaO2, and [Hb] (CaO2 = (1.34 x [Hb] x SaO2) 185 
+ (0.003 x PaO2). 186 
Upon initial arrival (day 1), blood pressure was assessed using an automated blood 187 
pressure cuff (HEM775CAN, Omron Healthcare). During the haemodilution protocol, blood 188 
pressure was assessed continuously by means of intra-radial pressure through the radial arterial 189 
catheter and was corrected to manual brachial blood pressure measurements (i.e. auscultation). A 190 
portable ultrasound (Vivid Q, GE Healthcare, Piscataway, NJ, USA) was used for the 191 
echocardiography assessment of cardiac output (Q). Participants were rolled into the left lateral 192 
decubitus position whereby a trained cardiac sonographer acquired parasternal and apical images. 193 
Stroke volume (SV) was calculated from the diameter of the left ventricular outflow tract 194 
diameter and the velocity-time integral from a five-chamber view (Lang et al., 2015). Reliability 195 
values for a range of echocardiographic variables from our group have previously been reported 196 
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(Stembridge et al., 2014). Heart rate was obtained from the R-R intervals recorded from a three 197 
lead ECG and multiplied by SV to calculate Q.  198 
 199 
Assessment of total blood volume  200 
Total blood volume was determined using the previously validated carbon monoxide 201 
rebreathing method, as described in detail elsewhere (Schmidt & Prommer, 2005). Using a 202 
custom glass spirometer (Blood Tec) and a 5-liter reservoir bag of 100 % O2, participants were 203 
instructed to maximally inhale a specific volume of carbon monoxide (0.8 mL · kg
-1
) which was 204 
inserted into the apparatus mid inspiration. Participants then held their breath at maximal 205 
inspiration for 10 seconds before rebreathing on the apparatus for two-minutes. A venous blood 206 
sample was obtained at baseline and seven minutes following onset of the carbon monoxide 207 
rebreathing to determine total haemoglobin [Hb] and carboxyhaemoglobin (ABL 90; 208 
Radiometer). Expired carbon monoxide was measured using a portable carbon monoxide analyzer 209 
(Dräger Pac 3500; Draeger Safety) at baseline and at four- and seven-minutes post rebreathe 210 
onset. Total red cell volume assessed by this measure was used to accurately calculate total blood 211 
volume pre- and post- haemodilution in conjunction with Hct %. Blood volume post 212 
haemodilution was calculated using the initial blood volume, and Hct % recorded from arterial 213 
blood samples pre- and post- haemodilution (i.e. HctInitial x blood volumeInitial = HctFinal x blood 214 
volumeFinal). 215 
  216 
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Data and Statistical Analyses  217 
Statistical analyses were performed using IBM SPSS 24. All data is reported as mean ± 218 
standard deviation. Linear mixed effects models, with repeated measures compound symmetry 219 
covariance structures, were used to determine significant changes in CBF, arterial blood gases, 220 
and cardiovascular variables from initial arrival and pre- vs post-haemodilution (fixed factor: 221 
time, random factor: subjects). Estimated CBF was calculated using the slope of the response 222 
between gCBF and Hct, pre- to post-haemodilution, multiplied by the change in Hct required to 223 
elicit a full reversal of haemoconcentration to initial arrival levels in individual participants. The 224 
“estimated” CBF was compared to initial arrival using a paired t-test. A linear mixed effects 225 
model analysis with repeated measures (compound symmetry covariance structure) was used to 226 
determine cerebrovascular reactivity to changes in CaO2 during the acclimatization process (day 1 227 
to pre hemo; condition 1) and during haemodilution (pre hemo to post hemo; condition 2). The 228 
dependent variable was gCBF, while CaO2 and condition were fixed effects. Subjects were 229 
included as a random effect and MAP and PaCO2 were added as co-variates, which improved the 230 
model fit (-2 Log Likelihood). This was repeated for ICA and VA flow as well. Relative changes 231 
in ICA and VA flow and reactivity were compared using a t-test following acclimatization and 232 
haemodilution to examine regional CBF differences. Finally, linear regression analysis was 233 
performed between both ΔgCBF and gCBF reactivity versus days spent at altitude to delineate the 234 
effect of testing day. Significance was set at P<0.05 for all statistical analyses.  235 
  236 
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RESULTS  237 
Arterial blood content changes  238 
Arterial blood metrics are presented in Table 1. Following one-week of acclimatization at 239 
5050 m, [Hb] and Hct were elevated and then subsequently decreased following haemodilution. 240 
However, [Hb] (P<0.01) and, Hct (P<0.001), were not reduced to their initial arrival levels and 241 
remained slightly elevated following haemodilution. Both PaO2 and SaO2 increased following 242 
acclimatization (SaO2, P<0.01; PaO2, P<0.001) and remained unchanged following 243 
haemodilution (SaO2, P=0.78; PaO2, P=0.79). Though PaCO2 significantly decreased following 244 
acclimatization and following the haemodilution protocol, pH was only altered (increased) 245 
following acclimatization, but remaining unchanged with haemodilution (P=0.39).   246 
 247 
Cardiovascular variables  248 
Resting cardiovascular data are presented in Table 2. Following acclimatization mean 249 
arterial pressure (MAP) was elevated (P=0.03), but did not increase further with haemodilution 250 
(P=0.32). Following haemodilution MAP was higher compared to initial arrival (P<0.01). Heart 251 
rate did not decrease following acclimatization (P=0.29), but was reduced following 252 
haemodilution compared to initial arrival (P=0.03). Notably, heart rate did not change pre- to 253 
post-haemodilution (P=0.15). Stroke volume decreased following acclimatization (P<0.01) and 254 
then increased following hemodilution (P=0.02). Following haemodilution, SV was not 255 
statistically different compared to initial arrival (P=0.051). These changes ultimately led to a 256 
reduction in Q following acclimatization (P<0.01), whereby Q remained below initial arrival 257 
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values following haemodilution (P=0.01). However, Q was not altered following haemodilution 258 
(P=0.62).  259 
  260 
CBF Results  261 
Cerebrovascular results are presented in Figure 2. Following approximately one-week at 262 
5050 m gCBF decreased by 20.9 ± 23.6% from 843.8 ± 160.2 to 619.6 ± 135.9 mL · min
-1
 263 
(P<0.001). This decrease was mediated by reductions in blood flow through both the ICA and VA 264 
(-14.2 ± 23.2%; P<0.01 and -22.3 ± 33.2%; P<0.01, respectively) (Figure 2). Following the 265 
haemodilution trial, gCBF was elevated by 15.3 ± 18.8% to 714.1 ± 203.5 mL · min
-1
 (P=0.045) 266 
due to an increase in ICA blood flow (+15.7 ± 19.7%; P=0.03) while blood flow in the VA only 267 
increased marginally and non-significantly (+15.5 ± 28.4%; P=0.305). Post haemodilution, gCBF 268 
remained significantly lower compared to initial arrival at high-altitude (P=0.033). At each time 269 
point, gCBF was regulated to the extent that CDO2 was unaltered across acclimatization (126.2 ± 270 
25.5 vs. 114.4 ± 22.7 mL · min
-1
) and hemodilution (121.6 ± 30.2 mL · min
-1
; main effect: 271 
P=0.302). No regional differences were observed between the relative changes in ICA and VA 272 
flow following acclimatization (-14.20 ± 23.15 vs -22.34 ± 33.16 %; P=0.10) or following 273 
haemodilution (15.72 ± 19.67 vs 15.52 ± 28.36 %; P=0.98). Linear regression analysis indicated 274 
there was no relationship between ΔgCBF and day of testing (R
2
=0.191; P=0.135). 275 
  276 
Blood volume  277 
 Blood volume data prior to and following haemodilution are presented in Table 3. Pre 278 
haemodilution, individual blood volumes ranged from 5.47 to 7.75 L with a mean of 6.18 ± 0.83 279 
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L. Of this, red cell volume accounted for 3.07 ± 0.49 L while plasma volume accounted for 3.11 280 
± 0.40 L. Assuming blood volume and hematocrit were relatively unchanged within 24 hrs 281 
following the carbon monoxide rebreathe assessment, blood volume post haemodilution was 282 
calculated based on the pre-haemodilution blood data. From these calculations, the mean increase 283 
in plasma volume and thus total blood volume observed following saline infusion was 0.54 ± 0.14 284 
L.  Notably, hydration status, as assessed by arterial blood osmolarity was not different pre- to 285 
post-haemodilution (288.14 ± 2.21 vs 289.00 vs 2.11 mmol · Kg
-1
) and falls within euhydration 286 
ranges (Armstrong et al., 2010). 287 
  288 
Mathematical estimation of CBF with a fully normalized Hct  289 
Despite the large saline infusion utilized (2.10 ± 0.28 L), the haemodilution protocol 290 
failed to fully revert Hct to initial arrival values (Table 1) and estimations based on total Hb mass 291 
and Hct concentration indicate on average 540 mL of saline remained within the vasculature at 292 
the time of measurement. Thus, an estimation of the CBF that would occur at a fully reversed 293 
haemoconcentration was utilized. The group mean regression for ΔgCBF (mL · min
-1
) per ΔHct 294 




 with individual values ranging from -17.96 to 82.33 mL · min
-1
 · 295 
Hct
-1
. Utilizing these reactivity slopes on an individual subject basis, we calculated that CBF 296 
would have increased to 790.5 mL · min
-1
 had Hct been reduced by an additional 3.1% and fully 297 
restored to the initial arrival value of ~42.5 %. Cumulatively, addition of this theoretical change 298 
in Hct leads to an overall 165.46 ml · min
-1
 increase in gCBF from pre- to post-hemodilution. 299 
This is inclusive of the experimentally elicited increase and additional estimated change (Figure 300 
2). While accounting for the change in CBF with full normalization of Hct statistically eliminates 301 
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the difference between initial arrival gCBF and that of the theoretical post-hemo gCBF (843.8 ± 302 
160.2 vs. 790.5 ± 266.8 mL · min
-1
; P=0.62), this increase in gCBF is not sufficient to explain the 303 
entire CBF response during acclimatization, which was a 224.13 ml · min
-1
 decrease. Indeed, 304 




  307 
CBF reactivity to CaO2  308 
Reactivity values from the linear mixed effects modelling are reported as mean ± SD 309 
(Figure 3). Following one-week of acclimatization and haemodilution gCBF reactivity was 310 






)] P=0.72). Additionally there 311 














)]; P=0.56) 313 
between acclimatization and haemodilution. Additionally, there were no differences detected in 314 





respectively)] following haemodilution (P=0.97). No regional differences between relative ICA 316 
and VA reactivity to CaO2 were observed following acclimatization (-1.80 ± 22.14 vs -9.18 ± 317 









)]; P=0.23). Linear regression analysis indicated there was no relationship between gCBF 319 
reactivity and day of testing (R
2
=0.209; P=0.116). 320 
 321 
  322 
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DISCUSSION  323 
This study aimed to mechanistically examine the degree to which haemoconcentration at 324 
high-altitude contributes to changes in CBF during acclimatization. The main findings of this 325 
study were that; 1) Similar to previous studies, elevations in CaO2 through increases in Hct, as 326 
well as PaO2, occurred following approximately one-week at high-altitude, resulting in a 327 
reduction in CBF but maintained CDO2 (Severinghaus et al., 1966; Huang et al., 1987; Jensen et 328 
al., 1990; Baumgartner et al., 1994; Lucas et al., 2011; Willie et al., 2014; Subudhi et al., 2014); 329 
2) Following haemodilution, an absolute reduction in Hct by ~4 % resulted in a significant 330 
increase in gCBF; however, this response was blunted compared to that during acclimatization 331 
where CBF did not return to initial arrival values. Further, changes in CBF following 332 
haemodilution and mathematical extension of this response indicate that haemoconcentration is 333 
responsible for ~74% of the decrease in CBF observed during acclimatization to high-altitude. 334 
This finding is further supported when the tight coupling of CBF to CaO2 is considered (Brown et 335 
al., 1985). Indeed, CBF both during acclimatization and following haemodilution appears to be 336 
tightly dictated by changes in CaO2. These findings imply that though ventilatory acclimatization 337 
and elevations in haematocrit occur concomitantly during acclimatization, the 338 
haemoconcentration response contributes to the CBF response during acclimatization to a greater 339 
degree at high-altitude.   340 
  341 
Cerebral Blood Flow  342 
Increased CBF in response to a reduction in CaO2 has been observed in previous studies, 343 
which demonstrates the brain’s ability to maintain CDO2 during hypoxemia (Ainslie et al., 2014). 344 
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This relationship is further evidenced by the reduction in CBF that occurs concomitant to 345 
increased CaO2 with acclimatization to high-altitude [reviewed in: (Ainslie & Subudhi, 2014)]. 346 
Therefore, it appears that CBF is regulated to maintain convective oxygen delivery to the brain. 347 
However, the relative contribution that haemoconcentration has on the reduction in CBF observed 348 
across acclimatization had not yet been investigated.   349 
Notably, due to the rapid diffusion of saline out of the intravascular space (Greenfield et 350 
al., 1989), Hct was not fully reversed to values observed upon initial arrival to high-altitude. 351 
However, as Hct has a linear inverse relationship with CBF through its relationship with CaO2 352 
(Brown & Marshall, 1985; Ainslie et al., 2014), the fully reversed response can be calculated by 353 
extrapolating this linear inverse relationship (Figure 2). Following mathematical correction to 354 
estimate the influence of a full reversal of haemoconcentration (see “Mathematical estimation of 355 
CBF with a fully normalized Hct”), gCBF did not completely return to initial arrival values 356 
despite the lack of statistical difference between pre-acclimatization and the theoretical post-357 
haemodilution CBF. The increase in gCBF following haemodilution (and mathematical extension 358 
of this increase) explained 74% of the reduction in gCBF observed following acclimatization. 359 
This suggests that the majority of the reduction in gCBF following one-week of acclimatization is 360 
mediated through increases in [Hb] and Hct, and their subsequent influence on CaO2. This is in 361 
agreement with recent estimations made by our group (Hoiland et al., 2018).  362 
Cerebrovascular hypoxic reactivity did not differ between acclimatization and 363 
haemodilution, highlighting previous findings demonstrating that CBF is primarily governed by 364 
changes in CaO2 and suggests that the difference in the CBF responses between acclimatization 365 
and haemodilution are not due to alterations in hypoxic reactivity. Therefore, it stands to reason 366 
that the difference between initial arrival CBF and following haemodilution (and correction for 367 
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full restoration of Hct) is primarily a result of ventilatory acclimatization whereby SaO2, PaO2, 368 
and pH are also elevated from initial arrival at high-altitude. Indeed, SaO2 and PaO2 were 5.0% 369 
and 6.1 mmHg higher following acclimatization, respectively, while pH was increased by 0.03 370 
units (Table 1). Given SaO2, PaO2, and pH were unaltered during haemodilution, their influence 371 
on cerebral vasomotor tone would have been unaltered and likely explains the difference between 372 
initial arrival and post-haemodilution CBF.  373 
Differences in regional CBF have been noted at high-altitude and in hypoxia with an 374 
apparent preference of flow to the posterior regions of the brain which houses the primary centers 375 
for regulating physiological function upon arrival to high-altitude (Subudhi et al., 2014; 376 
Feddersen et al., 2015) and during exposure to normobaric hypoxia (Willie et al., 2012). Of note, 377 
we did not observe any significant regional differences between relative changes in flow 378 
following acclimatization or haemodilution. Further, no differences were observed in the hypoxic 379 
reactivity between the ICA and VA. This finding agrees with previous work from our group 380 
conducted at the same altitude in subjects using acetazolamide (Willie et al., 2014). Differences 381 
between these findings and previous research showing regional flow disparities may be related to 382 
the methodology of data collection, primarily the blood flow measurement (transcranial Doppler 383 
ultrasound vs duplex ultrasound) and the severity and mode of exposure to the hypoxic stimulus 384 
(Hoiland et al., 2018; Willie et al., 2018) whereby a more severe step change or exposure may 385 
necessitate regional blood flow prioritization to the posterior circulation as a form of survival 386 
response. Further, an important consideration is that while these regional differences appear to be 387 
more prevalent at highly localized levels (Binks et al., 2008; Lawley et al., 2017), bulk flow 388 
measures at the VA and ICA may fail to detect these differences in some studies given that flow 389 
measures at these sites (VA & ICA) represent the summation of multiple discrete brain regions. 390 
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Further, differences in reactivity that have been noted at high-altitude are thus likely not 391 
attributable to changes in Hct based on our results.   392 
Following acclimatization, PaO2 and SaO2 increased through well documented 393 
mechanisms of ventilatory acclimatization [reviewed in; (Hoiland et al., 2018)]. Both were 394 
unaltered following haemodilution, isolating any effects of reversing ventilatory acclimatization 395 
induced blood gas changes from our CBF changes attributed to acclimatization/Hct. Thus, the 396 
persisting influence of SaO2 and PaO2 may represent the remaining stimulus for lower CBF post 397 
haemodilution compared to initial arrival. Further, while pH was unaltered following 398 
haemodilution, both pre- and post-haemodilution pH were higher than initial arrival. This may 399 
also be driving a reduction in CBF and indicate our results may in fact be underestimating (albeit 400 
modestly) the influence of haemoconcentration on CBF at altitude.  401 
 402 
  403 
Methodological considerations  404 
  405 
Effect of viscosity on CBF  406 
Alterations in Hct occurring both chronically during acclimatization (increases) and 407 
acutely during haemodilution (decreases) will lead to concomitant changes in whole blood 408 
viscosity, which may subsequently affect flow through the vasculature. However, experimental 409 
study has to date refuted this [(Brown & Marshall, 1985) reviewed in (Hoiland et al., 2016)]. 410 
Indeed, a reduction in blood viscosity through plasma exchange in patients with paraproteinemia, 411 
whereby CaO2 and PaCO2 were constant, does not alter CBF (Brown & Marshall, 1985). While at 412 
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odds with basic physical principles (i.e., Poiseuille’s Law), it is important to consider that the 413 
cerebral vasculature is a complex network of compliant vessels conveying a non-newtonian fluid. 414 
Thus, the conditions do not reflect those in which Poiseuille’s Law was defined. Further, 415 
alterations in blood viscosity can influence vascular paracrine signalling. To speculate, reductions 416 
in blood viscosity would reduce the direct resistive effects of blood flow through the vessel, 417 
however, the shear stress stimuli induced by viscosity would also be reduced, potentially limiting 418 
dilation through reduced stimulation of shear dependent pathways (Melkumyants, Balashov, & 419 
Khayutin, 1989). This would act to increase vascular resistance. Thus, it is likely that a balance 420 
exists between these two stimuli, possibly explaining why viscosity has been previously shown to 421 
have a negligible effect on CBF (Brown & Marshall, 1985). Indeed, that haemodilution leads to 422 
greater increases in CBF than blood flow to other vascular beds (Crystal & Salem, 2002; Van 423 
Bommel et al., 2002) indicate the increases in CBF observed during haemodilution reflect active 424 
vascular regulation.  425 
   426 
Effect of PaCO2 and pH   427 
As expected, PaCO2 was significantly reduced following one-week of acclimatization at 428 
high-altitude due to ventilatory acclimatization (Rahn & Otis, 1949). However, we also observed 429 
a 2.6 mmHg reduction in PaCO2 following haemodilution, though both PaO2 and SaO2 were 430 
unchanged. This decrease in PaCO2 in the presence of unchanged PaO2 and SaO2 has been 431 
reported in a previous saline infusion study (Prisk et al., 2010) and is likely due to the dilutional 432 
acidosis effect of the saline solution (Muir et al., 1975). Notably, at least at sea level, PaCO2 has 433 
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been shown to effect ICA and VA flow by ~6-8 % per 1 mmHg change in PaCO2 (Willie et al., 434 
2012;  435 
Hoiland et al., 2015). These observations indicate that, upon correction for this small alteration in 436 
PaCO2, the CBF response would be greater following haemodilution, suggesting that the 437 
contribution of Hct on the CBF response would be more substantial. However, as PaCO2 438 
primarily alters CBF through changes in arterial pH - which notably was not different pre to post 439 
haemodilution - the difference in PaCO2 pre-to post-haemodilution likely had a negligible effect.  440 
  441 
Blood volume expansion  442 
 Due to the logistical constraints and remote nature of the high-altitude expedition, a 443 
hypervolemic hemodilution protocol using saline infusion was utilized as opposed to a 444 
normovolemic haemodilution protocol in which blood volume would be maintained. However, 445 
this may be most appropriate as the initial increases in Hct observed at altitude are due to a 446 
reduced plasma volume (Siebenmann et al., 2015), thus our intervention manipulated Hct in the 447 
same manner as the environmental stress of high-altitude hypoxia. Though the volume of fluid 448 
utilized in this protocol was relatively large in relation to the overall blood volume of 449 
participants, the crystalloid properties of the fluid infused and the time at rest between measures 450 
resulted in a large portion of the infused saline leaving the vasculature (Greenfield et al., 1989). 451 
This is primarily evidenced by the relatively marginal reduction in hematocrit compared to 452 
volume infused and blood volume data which indicates only 540 mL of saline remained within 453 
the vasculature at the time of CBF measurement. Further, if increases in blood volume resulted in 454 
alterations in CBF, this would be expected to coincide with alterations in cardiac parameters, (i.e. 455 
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increased Q). Of note, neither of these variables were significantly elevated by hemodilution 456 
suggesting there was no direct impact of volume expansion on CBF changes in this study.   457 
 458 
  459 
CONCLUSIONS  460 
This study was the first to experimentally investigate the degree to which CBF 461 
acclimatization is driven by haemoconcentration. Through haemodilution, we were able to 462 
determine that, following one-week of acclimatization, the primary mechanism contributing to the 463 
CBF response during acclimatization response is generated by diuresis and erythropoiesis-464 
mediated increases in [Hb] and Hct, while the remaining contribution to the CBF response during 465 
acclimatization response is likely attributable to ventilatory acclimatization.   466 
    467 
 468 
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TABLES  592 
  593 
Table 1. Arterial blood gases at high altitude.  594 
  Arrival at 5050m  Pre-Haemodilution  Post-Haemodilution  
CaO2 (mL · dL)  15.4 ± 1.6  18.6 ± 1.3*  17.2 ± 1.0*†  
Hct (%)  42.5 ± 2.5  49.6 ± 2.5*  45.6 ± 2.3*†  
[Hb] (g · dL)  14.3 ± 0.8  16.2 ± 0.8*  14.9 ± 0.8*†  
29 
 
PaCO2 (mmHg)  29.6 ± 1.8  23.6 ± 2.1*  21.0 ± 1.5*†  
pH  7.47 ± 0.02  7.50 ± 0.02*  7.49 ± 0.02*  
PaO2 (mmHg)  40.6 ± 4.7  46.7 ± 4.2*  47.0 ± 3.4*  
SaO2 (%)  78.3 ± 5.6  83.3 ± 4.1*  83.7 ± 3.5*  
* significant difference from arrival at 5050m  595 
† significant difference between pre- and post-haemodilution   596 
30 
 
Table 2. Cardiovascular parameters upon arrival to high-altitude and pre- and post-597 
haemodilution  598 
  Arrival at 5050m  Pre-Haemodilution  Post-Haemodilution  
MAP (mmHg)  99±12  108±10*  111±9*  
HR (bpm)  65±18  58±11  53±12*  
SV (mL)  69±13  54±11*  63±8.8†  
Q (L · min
-1
)   4.45±1.52  3.09±0.65*  3.28±0.65  
* significant difference from arrival at 5050m  599 
† significant difference between pre- and post-haemodilution   600 
31 
 









Volume (L)  
Plasma 
Volume (L)  
Blood 




Volume (L)  
Plasma  




1  47.4  2.661  2.953  5.613  43.4  2.661  3.470  6.131 
2  53.2  2.911  2.561  5.472  48.9  2.911  2.989  5.900  
3  50.2  2.569  2.549  5.118  46.6  2.569  2.923  5.492  
4  50.8  3.555  3.443  6.997  46.1  3.555  4.110  7.665  
5  49  3.799  3.954  7.753  45.4  3.799  4.550  8.349  
6  49  2.787  2.900  5.687  45.5  2.787  3.325  6.111  
7  49.8  2.927  2.951  5.878  45.2  2.927  3.522  6.449  
8  50.6  3.607  3.521  7.128  45.4  3.607  4.288  7.895  
9  50.8  3.474  3.365  6.839  45.6  3.474  4.094  7.569  
10  50.1  2.896  2.884  5.780  46.8  2.896  3.271  6.167  
11  52.9  3.695  3.290  6.985  49.3  3.695  3.747  7.442  
12  43.3  2.411  3.157  5.568  40.5  2.411  3.572  5.983  
13  47  2.604  2.936  5.540  43.6  2.604  3.619  6.223  
MEAN  49.5  3.069  3.113  6.181  45.6  3.069  3.652  6.721  
SD  2.6  0.486  0.396  0.834  2.3  0.486  0.492  0.924  
Individual blood volume data pre- and post-haemodilution. Plasma volume and total blood 602 
volume are derived from the Hct % and total Hct volume measured using a CO re-breath test 603 
performed one-day prior to the haemodilution protocol.    604 
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FIGURES  605 
  606 
  607 
Figure 1. Experimental overview of the study protocol. Participants ascended to 5050 m over a 608 
9-day period involving rapid ascent by plane to 2860 m, and ambulatory ascent onward to 5050 609 
m. Cerebral blood flow (CBF), arterial blood gases (ABGs), blood pressure (BP), cardiac output 610 
(Q) and heart rate (HR) were recorded at all three time points.   611 
 612 
 613 
Figure 2. Cerebral blood flow during acclimatization and following haemodilution. At the 614 
arrival time point, sample sizes were reduced for the internal carotid artery (ICA; n=11), vertebral 615 
artery (VA; n=11), and global cerebral blood flow (gCBF; n=10). Data was successfully collected 616 
in all participants (n=13) following one-week of acclimatization at 5050 m (pre-hemo) and 617 
following hypervolemic haemodilution (post-hemo). “Estimated” data (denoted by the grey 618 
background) are based on theoretical calculations for a fully normalized Hct (see “Theoretical 619 
calculation of CBF with a fully normalized Hct”). Blood flow was calculated to assume a 620 
complete reversal of haematocrit to initial arrival values (i.e. greater extent of haemodilution). 621 
Open circles represent individual data points with dotted lines tracking within subject changes. 622 
Black horizontal lines represent the average flow at each time point. * signifies a significant 623 
difference from arrival at 5050m. † signifies a significant difference pre- to post- haemodilution. 624 
Significance is set a  625 
P<0.05    626 
 627 
 628 
Figure 3. Cerebrovascular reactivity to acclimatization and haemodilution. Reactivity to 629 
changes in CaO2 was not different across acclimatization (Initial arrival to pre-hemo) compared 630 
to during haemodilution (pre-hemo to post-hemo). gCBF, global cerebral blood flow; ICA, 631 
internal carotid artery; VA, vertebral artery. No differences in reactivity were observed between 632 
the ICA and VA at any time point. Data are presented as mean ± SD.  633 
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